Diagnosis and therapy of alcoholic liver disease

被引:80
作者
Levitsky, J
Mailliard, ME
机构
[1] Univ Nebraska, Coll Med, Div Gastroenterol & Hepatol, Omaha, NE 68583 USA
[2] Univ Nebraska, Ctr Med, Dept Internal Med, Coll Med, Omaha, NE 68583 USA
[3] Vet Affairs Med Ctr, Omaha, NE USA
关键词
liver disease; alcoholic; corticosteroids; tumor necrosis factor-alpha; antibodies; monoclonal;
D O I
10.1055/s-2004-832937
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Alcoholic liver disease (ALD) presents considerable challenges to clinicians. Screening for alcohol abuse and alcoholism should be routine and repeated annually with close attention to signs and symptoms of liver disease. In patients with evidence of liver dysfunction or injury, consideration should be given to performance of liver biopsy for diagnosis and prognosis and prior to initiation of medication with the potential for significant side effects. Therapy depends on the spectrum of pathological liver injury: alcoholic fatty liver, alcoholic hepatitis, and cirrhosis. Abstention is the foundation of therapy for an alcohol problem. Alcoholic fatty liver should improve with abstention, but the similarity to the pathogenesis of nonalcoholic fatty liver and potential for progressive injury merits consideration of lipotropic agents. The continuing mortality, poor acceptance of corticosteroids, and identification of tumor necrosis factor-alpha (TNF-alpha) as an integral component has led to studies of pentoxifylline and, recently, anti-TNF antibody to neutralize cytokines in the therapy of severe alcoholic hepatitis. Antioxidant therapy of alcoholic cirrhosis has significant promise but will require large clinical trials.
引用
收藏
页码:233 / 247
页数:15
相关论文
共 173 条
  • [11] The effect of betaine in reversing alcoholic steatosis
    Barak, AJ
    Beckenhauer, HC
    Badakhsh, S
    Tuma, DJ
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1997, 21 (06) : 1100 - 1102
  • [12] Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study
    Becker, U
    Deis, A
    Sorensen, TIA
    Gronbaek, M
    BorchJohnsen, K
    Muller, CF
    Schnohr, P
    Jensen, G
    [J]. HEPATOLOGY, 1996, 23 (05) : 1025 - 1029
  • [13] CARBOHYDRATE-DEFICIENT TRANSFERRIN AND OTHER MARKERS OF HIGH ALCOHOL-CONSUMPTION - A STUDY OF 502 PATIENTS ADMITTED CONSECUTIVELY TO A MEDICAL DEPARTMENT
    BELL, H
    TALLAKSEN, CME
    TRY, K
    HAUG, E
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1994, 18 (05) : 1103 - 1108
  • [14] Light-to-moderate alcohol consumption and the risk of stroke among US male physicians.
    Berger, K
    Ajani, UA
    Kase, CS
    Gaziano, JM
    Buring, JE
    Glynn, RJ
    Hennekens, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) : 1557 - 1564
  • [15] BERNSTEIN J, 1975, J PHARMACOL EXP THER, V192, P583
  • [16] BIRD G, 1991, HEPATOLOGY, V14, P1097, DOI 10.1002/hep.1840140625
  • [17] BISSON JI, 1994, ALCOHOL ALCOHOLISM, V29, P315
  • [18] ADRENOCORTICOSTEROID THERAPY IN ALCOHOLIC HEPATITIS - PROSPECTIVE, DOUBLE-BLIND RANDOMIZED STUDY
    BLITZER, BL
    MUTCHNICK, MG
    JOSHI, PH
    PHILLIPS, MM
    FESSEL, JM
    CONN, HO
    [J]. AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1977, 22 (06): : 477 - 484
  • [19] BONKOVSKY HL, 1991, AM J GASTROENTEROL, V86, P1200
  • [20] Screening for problem drinking - Comparison of CAGE and AUDIT
    Bradley, KA
    Bush, KR
    McDonell, MB
    Malone, T
    Fihn, SD
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1998, 13 (06) : 379 - 388